-$0.12 Earnings Per Share Expected for Cerus Co. (NASDAQ:CERS) This Quarter

Analysts predict that Cerus Co. (NASDAQ:CERS) will post earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Cerus’ earnings, with estimates ranging from ($0.13) to ($0.10). Cerus also posted earnings of ($0.12) per share during the same quarter last year. The firm is expected to report its next quarterly earnings results on Tuesday, February 25th.

On average, analysts expect that Cerus will report full-year earnings of ($0.50) per share for the current financial year, with EPS estimates ranging from ($0.52) to ($0.46). For the next financial year, analysts forecast that the company will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.46) to ($0.24). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Cerus.

Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Cerus had a negative return on equity of 100.59% and a negative net margin of 100.38%. The business had revenue of $18.00 million during the quarter, compared to the consensus estimate of $17.69 million. During the same period in the prior year, the firm earned ($0.11) EPS. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year.

CERS has been the topic of a number of analyst reports. Stephens initiated coverage on shares of Cerus in a report on Thursday, August 22nd. They issued an “overweight” rating and a $8.00 target price on the stock. BidaskClub lowered shares of Cerus from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. Stifel Nicolaus initiated coverage on shares of Cerus in a report on Tuesday, August 27th. They issued a “buy” rating and a $7.00 target price on the stock. ValuEngine lowered shares of Cerus from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Finally, Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $7.63.

In other Cerus news, Director Timothy B. Anderson sold 18,795 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $5.40, for a total value of $101,493.00. Following the completion of the sale, the director now directly owns 177,649 shares of the company’s stock, valued at approximately $959,304.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Carol Moore sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $5.33, for a total transaction of $159,900.00. The disclosure for this sale can be found here. Insiders sold a total of 58,459 shares of company stock worth $312,129 in the last 90 days. 7.26% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of CERS. Sumitomo Mitsui Trust Holdings Inc. grew its position in Cerus by 444.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,049,385 shares of the biotechnology company’s stock worth $28,378,000 after purchasing an additional 4,121,845 shares in the last quarter. Nikko Asset Management Americas Inc. grew its position in Cerus by 434.1% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 5,049,385 shares of the biotechnology company’s stock worth $28,378,000 after purchasing an additional 4,103,996 shares in the last quarter. D. E. Shaw & Co. Inc. grew its position in Cerus by 147.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,503,500 shares of the biotechnology company’s stock worth $8,449,000 after purchasing an additional 896,994 shares in the last quarter. ARK Investment Management LLC grew its position in Cerus by 11.2% in the 2nd quarter. ARK Investment Management LLC now owns 8,493,022 shares of the biotechnology company’s stock worth $47,731,000 after purchasing an additional 853,589 shares in the last quarter. Finally, First Midwest Bank Trust Division grew its position in Cerus by 435.5% in the 2nd quarter. First Midwest Bank Trust Division now owns 915,165 shares of the biotechnology company’s stock worth $5,143,000 after purchasing an additional 744,254 shares in the last quarter. 74.26% of the stock is owned by institutional investors and hedge funds.

Shares of Cerus stock traded down $0.13 during trading on Tuesday, hitting $4.11. The company’s stock had a trading volume of 612,600 shares, compared to its average volume of 864,339. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.77 and a quick ratio of 2.31. Cerus has a 52 week low of $3.95 and a 52 week high of $6.88. The stock has a market cap of $607.59 million, a price-to-earnings ratio of -9.34 and a beta of 1.60. The stock has a 50-day moving average price of $4.61 and a two-hundred day moving average price of $5.16.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Read More: What is a capital gain?

Get a free copy of the Zacks research report on Cerus (CERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.